StockData

Pelthos Therapeutics vs Scilex

PTHS and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PTHS and SCLX compare

Pelthos Therapeutics is the larger company, worth 2.5 times as much as Scilex ($26.2M against $10.6M).

Pelthos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −200% compared with −1470% at Scilex.

Pelthos Therapeutics scores higher on the StockData Score (2 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPTHSSCLX
Size and price
Market cap$26.2M$10.6M
Share price$6.84$1.25
Change, 1 year−79.6%−93.0%
Change, 5 years–−99.6%
Beta (5Y)0.972.18
Employees9234
StockData Score
Total score2 (better)1
Valuation score11
Growth score00
Performance score00
Health score1 (better)0
Dividend score00
Valuation
P/S0.6×0.3× (better)
Growth
Revenue growth (TTM)–−28.5%
Revenue growth, 5Y average–5.1%
Profitability
Gross margin78.6%161% (better)
Operating margin−133% (better)−1136%
Net margin−200% (better)−1470%
Financial health
Interest coverage−7.8× (better)−22.2×
Current ratio1.98 (better)0.07
Altman Z-score−1.84 (better)−12.75
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions35.6%9.8%
Insider net buying, 12 months$794K (better)−$12.8M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.